Surgery offers the only real chance at cure, but most people never reach the operating room.
O cancro do pâncreas é uma das doenças que mais silenciosamente avança na vida humana — chegando, na maioria dos casos, quando já pouco resta para fazer cirurgicamente. Em Portugal, cerca de 1.400 pessoas recebem este diagnóstico por ano, a maioria já em fase avançada, num confronto que revela tanto os limites da medicina como a promessa crescente da ciência molecular. A história desta doença é, em parte, a história da detecção tardia; mas é também, cada vez mais, a história de como a investigação e a prevenção podem reescrever destinos.
- Oito em cada dez doentes chegam ao diagnóstico com a doença já disseminada, tornando a cirurgia — o único tratamento verdadeiramente curativo — inacessível para a grande maioria.
- Os sintomas iniciais são traiçoeiramente vagos, confundindo-se com outras condições e adiando o momento em que o tumor é finalmente identificado por imagem.
- Novos protocolos de quimioterapia pré-operatória estão a reduzir tumores antes considerados inoperáveis, aumentando o número de doentes que chegam à mesa de cirurgia com hipóteses reais de cura.
- A investigação molecular está a identificar biomarcadores que permitem personalizar o tratamento, substituindo a abordagem uniforme por terapias adaptadas às vulnerabilidades específicas de cada tumor.
- Dois terços dos factores de risco são potencialmente evitáveis — tabagismo, obesidade, sedentarismo — abrindo uma janela de prevenção que a ciência ainda não conseguiu traduzir em mudança colectiva de comportamento.
O cancro do pâncreas chega tarde. Quando a maioria dos doentes recebe o diagnóstico, a doença já se expandiu para além do alcance da cirurgia. Em Portugal, com cerca de 1.400 novos casos por ano — o terceiro cancro digestivo mais comum no país — esta realidade define tudo: apenas um em cada cinco doentes é candidato à operação que representa a única possibilidade real de cura.
A doença instala-se em silêncio. Os primeiros sinais — dor abdominal, perda de apetite, emagrecimento, fadiga — são suficientemente inespecíficos para pertencerem a muitas outras condições. Quando as imagens revelam o tumor, este já conquistou território além do pâncreas. A idade é o factor de risco mais evidente, com a maioria dos casos a surgir após os setenta anos, e os homens a adoecer com maior frequência do que as mulheres. O tabagismo é o principal factor adquirido modificável, seguido da obesidade. O consumo crónico de álcool, a diabetes, uma alimentação rica em gorduras animais e o sedentarismo também contribuem. Cerca de um em cada dez doentes tem história familiar da doença, embora menos de cinco por cento dos casos resultem de síndromes genéticas hereditárias. O dado mais encorajador: aproximadamente dois terços dos factores de risco relevantes são teoricamente preveníveis.
O diagnóstico melhorou. A tomografia computorizada e a ressonância magnética permitem mapear o tumor, enquanto a ecoendoscopia possibilita uma observação mais próxima da lesão e a recolha de biópsia sem cirurgia maior. O tratamento depende da extensão da doença e da condição do doente. Para quem não pode ser operado, a quimioterapia é a principal arma. Uma mudança significativa ocorreu nos últimos anos: novos regimes de quimioterapia pré-operatória têm conseguido reduzir tumores antes inoperáveis, aumentando o número de doentes elegíveis para cirurgia.
A investigação molecular trouxe uma revolução discreta. Cientistas identificaram biomarcadores que prevêem o comportamento tumoral e a resposta a fármacos específicos, abrindo caminho para tratamentos personalizados. Ensaios clínicos já decorrem em várias instituições portuguesas. A sobrevivência tem aumentado lentamente mas de forma mensurável na última década. Se os marcadores moleculares continuarem a afinar a selecção terapêutica, se mais doentes se tornarem candidatos cirúrgicos e se os factores de risco modificáveis forem levados a sério, a história natural desta doença pode mudar. O terreno está a começar a mover-se.
Pancreatic cancer arrives late. By the time most patients learn they have it, the disease has already spread beyond the reach of a surgeon's knife. This grim arithmetic shapes everything about how doctors in Portugal approach the disease: roughly four out of five people diagnosed with pancreatic cancer already have advanced illness, leaving only one in five as candidates for the surgery that remains the only genuinely curative option.
Portugal sees about 1,400 new cases each year, making pancreatic cancer the third most common malignancy of the digestive system in the country. The disease tends to announce itself quietly, if at all. In its early stages, patients may feel nothing. When symptoms do appear—abdominal pain, loss of appetite, weight loss, fatigue—they are vague enough to belong to a dozen other conditions. By the time imaging reveals the tumor, the cancer has usually claimed territory beyond the pancreas itself.
Age is the most obvious risk factor. Most cases emerge after age seventy, and men develop the disease more often than women. But age alone does not determine who gets sick. Smoking stands as the single most consequential habit a person can change; it is the primary acquired risk factor, followed closely by obesity. Chronic alcohol consumption, particularly in people with long-standing pancreatitis, raises the risk. So do diabetes, a diet heavy in animal fats, and a sedentary life. About one in ten patients have a family history of the disease, though fewer than five percent of all cases trace back to inherited genetic syndromes. The encouraging part: roughly two-thirds of the risk factors that matter are theoretically preventable.
Diagnosis has improved. When doctors suspect pancreatic cancer, they typically start with computed tomography or magnetic resonance imaging to map the tumor's location and size. If those scans reveal something suspicious, endoscopic ultrasound allows a closer look at the lesion itself and the surrounding pancreatic tissue, and it permits the doctor to take a tissue sample—a biopsy—without major surgery. For people at particularly high risk because of family history or known hereditary syndromes, screening programs exist, though they remain largely confined to research settings.
Treatment depends entirely on what the tumor looks like and what the patient can tolerate. Surgery offers the only real chance at cure, but most people never reach the operating room. For them, chemotherapy becomes the main weapon, sometimes used alone, sometimes combined with radiation. A significant shift has occurred in recent years: new chemotherapy regimens given before surgery have begun to shrink tumors enough that more patients become surgical candidates. The proportion of people eligible for potentially curative surgery has climbed, and these patients—the ones whose tumors can actually be removed—enjoy the most favorable odds.
The past decade has brought a quiet revolution in how researchers understand pancreatic cancer at the molecular level. Scientists have identified biomarkers that predict how a tumor will behave and how it might respond to specific drugs. This knowledge is beginning to reshape treatment: instead of giving every patient the same chemotherapy, doctors may soon be able to match drugs to the particular vulnerabilities of each person's cancer cells. Clinical trials testing these approaches are already underway at several Portuguese institutions, and enrollment in such studies should be considered at any stage of the disease.
Survival has inched upward over the past decade—slowly, but measurably. The trajectory suggests that the coming years could bring more substantial gains. If molecular markers continue to refine treatment selection, if more patients become eligible for surgery through better pre-operative chemotherapy, and if people take seriously the modifiable risk factors, the natural history of this disease could shift significantly. For now, pancreatic cancer remains formidable. But the ground is beginning to move.
Citas Notables
The only treatment curativo is surgery— Dr. Eduardo Rodrigues-Pinto, gastroenterologist and member of the Portuguese Gastroenterology Society
Survival has improved slowly but consistently over the past decade— Dr. Eduardo Rodrigues-Pinto
La Conversación del Hearth Otra perspectiva de la historia
Why does pancreatic cancer stay hidden for so long?
The pancreas sits deep in the abdomen, tucked behind other organs. Early tumors don't press on anything that hurts. By the time a patient feels pain or loses weight, the cancer has usually already spread. It's a matter of anatomy and biology working against us.
So surgery is the only real cure?
Yes. Chemotherapy can shrink tumors and extend life, but only surgery removes the cancer completely. That's why the new pre-surgical chemotherapy protocols matter so much—they're making more tumors small enough to operate on.
What's changed in the last decade?
We've moved from treating all pancreatic cancers the same way to understanding the molecular differences between tumors. We can now identify which drugs will work best against a specific patient's cancer cells. That's a fundamental shift.
How preventable is this disease?
Two-thirds of the risk factors are things people can control: smoking, weight, diet, exercise, alcohol. If someone quit smoking and maintained a healthy weight, they'd eliminate the two biggest modifiable risks. That's real opportunity.
What gives you hope?
The fact that survival is improving, even if slowly. And the fact that more patients are becoming surgical candidates. The molecular research is opening doors we couldn't see five years ago.